
Genoskin
Salem, MA, United Statesgenoskin.comFrom their website, Nov 2026
- ISO 9001
Work here? Claim this listing
About
Genoskin provides ex vivo human skin models, human primary mast cells, and custom non-clinical studies for drug, vaccine, medical device, cosmetic, and academic research. The company operates in France and the United States and serves customers worldwide.
Services
Injection Site Toxicology
Assesses local toxicity and inflammatory responses after injection in ex vivo human skin.
ADME, DMPK & toxicology
Injection Site Reaction Testing
Evaluates local immune activation and tissue response to injectable therapeutics in ex vivo human skin.
ADME, DMPK & toxicology
Local Tolerance Studies
Tests cytotoxicity and local tolerance at contact sites using ex vivo human skin models.
ADME, DMPK & toxicology
Toxicity Pilot Study
Runs a 5-day feasibility study in living human skin to generate early local toxicity and immune response data for injectables.
ADME, DMPK & toxicology
Inflammatory Skin Disease Research
Supports studies in inflammatory skin disease using ex vivo human skin platforms.
Psoriasis Research
Supports anti-psoriasis studies using human skin models.
Type-2 Barrier Impairment Research
Supports research on barrier impairment using human skin platforms.
Hidradenitis Suppurativa Research
Supports research on hidradenitis suppurativa using human skin models.
9 more services
- Vaccine Development
- Topical and Transdermal Evaluation
- Human Mast Cells Services
- Assays and Readouts
- Spatial Biology Platform
- Bioinformatic Analysis
- Cosmetic Claim Substantiation
- Barrier Function Studies
- Topical Delivery
- What to send
- Donated human skin
- Injectable therapeutic or vaccine
- Healthy human skin for HypoSkin studies
Capabilities
- Assays and studies
- Toxicology
- Antibodies
- ADCs
- Peptides
- Histopathology
- H&E staining
9 more
- TUNEL assays
- Multiplex cytokine analysis
- Transcriptomics
- Multiplexed proteomics
- Bioinformatics
- Gene expression signatures
- Histology-based assessments
- Secreted inflammatory mediators
- Biomarker analysis
- Scale and capacity
- Up to 10 days in culture
- 5-day ex vivo pilot study
- One donor before multi-donor investigation
- Therapeutic areas
- Inflammatory skin disease
- Psoriasis
- Hidradenitis suppurativa
- Type-2 barrier impairment
- Vaccine development
- Local toxicity
- Immunotoxicity
- Allergy
Instruments and platforms
- Next-generation transcriptomics
- Multiplexed proteomics
Modalities and species
- Modalities
- Small molecule
- Antibody
- ADC
- Peptide
- mRNA
- Cell therapy
- Vaccine
- Species and models
- Donated human skin
- Healthy human skin
- HypoSkin
- NativeSkin
- WoundSkin
- HairSkin
3 more
- Human Mast Cells
- Connective-tissue type human primary mast cells
- Healthy donor mast cells
Certifications
As the company states them, with the certificate or registry record where there is one.
ISO 9001Self-reported
Scope: Genoskin SAS facility in France; human tissue sourcing, biobanking, skin model production, preclinical testing services,
GLPSelf-reported
Company
- Type
- CRO
- Founded
- 2017
- Ownership
- Small business, as registered with SAM.gov or stated on their site
Locations
- Based in
- Salem, MA, United States
- Sites
- Toulouse, France · Salem, MA, United States
- Serves
- Worldwide, North America
Public records
- Biocom California CRO directory
- ex vivo human skin models, new approach methodologies, safety toxicology models, skin immunology, subcutaneous injection research source